Resources with keywords: treatment
Guidance published by the Minnesota Department of Health for health practitioners involved in the care for patients potentially exposed to rabies virus.
Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC; NIH COVID-19 Treatment Guidelines Panel; Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J.
In March 2020, the White House Coronavirus Task Force determined that clinicians in the United States needed expert treatment guidelines to optimally manage patients with COVID-19, a potentially life-threatening disease caused by a new pathogen for which no specific treatments were known to be effective.
Covers the use of personal protective equipment, testing, antiviral treatment, patient investigations, monitoring of exposed persons, and antiviral chemoprophylaxis of exposed persons
Covers the use of personal protective equipment, testing, antiviral treatment, patient investigations, monitoring of exposed persons, and antiviral chemoprophylaxis of exposed persons
Reis G, et.al.
Among predominantly vaccinated outpatients with Covid-19, the incidence of hospitalization or an emergency department visit was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received placebo.
Susan McLellan, MD, MPH
